Clinical trials: Primary Sjogren's Syndrome
Sjögren's Syndrome
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from…
- Trial name
- NCT02843659
- Testing
- BMS-931699, BMS-986142
- Where
- 34 sites in United States, Australia and 9 more
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Sjogren's Syndrome
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
This is a randomized, double-blind, placebo-controlled, two-treatment arm, parallel-group study designed to evaluate the effects of RO5459072 treatment on disease activity and symptoms of Sjogren's syndrome in adult participants…
- Trial name
- NCT02701985
- Testing
- RO5459072
- Where
- 31 sites in United States, France and 4 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Sjogren's Syndrome
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome
Background: An autoimmune disease is one in which the immune system attacks a person's own body. Sjogren's syndrome (SS) is an autoimmune disease. It often involves multiple systems and organs of the body.
- Trial name
- NCT04496960
- Testing
- tofacitinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Primary Sjögren's Syndrome
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome(pSS)
- Trial name
- NCT02291029
- Testing
- CFZ533 active - Cohort 1, CFZ533 active - Cohort 2, CFZ533 active -Cohort 3
- Where
- 9 sites in United States, Germany and 3 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Sjogren's Syndrome
A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
The present study will examine the role of circulating RNA complexed with autoantibodies and immune complexes and its role in activation of inflammatory pathways in patients with primary Sjogren's syndrome.
- Trial name
- RSLV-132 (NCT03247686)
- Testing
- RSLV-132
- Where
- 2 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- Resolve Therapeutics
Sjögren's Syndrome, Xerostomia
Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects
Background: Sjögren's syndrome is an autoimmune disease (where the immune system attacks normal body tissues) that affects the salivary glands.
- Trial name
- NCT01316770
- Testing
- Dexamethasone Parotid Irrigation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Sjogren's Syndrome
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.
- Trial name
- NCT04968912
- Testing
- Nipocalimab, Standard of Care Treatment
- Where
- 69 sites in United States, France and 8 more
- Volunteers
- 163 people
- Sponsor
- Janssen Research & Development, LLC
Sjögren's Syndrome, Sjogren's Syndrome
Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)
Primary Objective: To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by the change of the European League Against…
- Trial name
- phaethuSA (NCT04572841)
- Testing
- SAR441344
- Where
- 36 sites in United States, Argentina and 10 more
- Volunteers
- 84 people
- Sponsor
- Sanofi
Primary Sjögren Syndrome
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
This is a first exploration of GLPG3970 in participants with active primary Sjogren's Syndrome (pSS) to evaluate the efficacy, safety and tolerability and to determine its pharmacokinetics (PK) profile compared to placebo.
- Trial name
- GLIDER (NCT04700280)
- Testing
- GLPG3970
- Where
- 10 sites in Germany, Greece and 3 more
- Volunteers
- 31 people
- Sponsor
- Lakefront Biotherapeutics NV
KERATOCONJUNCTIVITIS SICCA, XEROSTOMIA
Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome
This study was designed to test the efficacy and safety of low laser therapy to treat the xerostomia of patients with primary Sjogren's Syndrome.
- Conditions
- KERATOCONJUNCTIVITIS SICCA, XEROSTOMIA, SICCA SYNDROME, PRIMARY SJOGREN SYNDROME
- Trial name
- NCT02066896
- Testing
- Lasertherapy
- Where
- Brazil
- Volunteers
- 66 people
- Sponsor
- Federal University of São Paulo
Primary Sjögren's Syndrome
Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients
The purpose of this study is to assess the effect of multiple intravenous infusions of S95011 compared to placebo in reducing disease activity in patients with primary Sjögren's syndrome.
- Trial name
- NCT04605978
- Testing
- S95011 concentrate for solution for infusion
- Where
- 19 sites in United States, Australia and 5 more
- Volunteers
- 48 people
- Sponsor
- Institut de Recherches Internationales Servier
Primary Sjogren Syndrome
Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)
The purpose of this study was to determine the dose-response relationship of VAY736 for key efficacy and safety parameters
- Trial name
- NCT02962895
- Testing
- VAY736
- Where
- 56 sites in United States, Argentina and 17 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Sjogren's Syndrome
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
This study is a multi-national, multi-center, double-blind (sponsor open), randomized, placebo-controlled trial in subjects with active primary Sjögren's syndrome designed to understand the safety and tolerability profile of…
- Trial name
- NCT02631538
- Testing
- Belimumab, Rituximab
- Where
- 36 sites in Argentina, Canada and 8 more
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline